Structure Therapeutics is trading 4.1% lower at $35.38, with the decline appearing mainly linked to weaker broad-market sentiment. - The Nasdaq is down 1.04%, as investors remain cautious amid higher oil prices and Treasury yields. - No clear company-specific announcement, earnings update, or analyst action was identified for September 23, 2026. - Recent obesity-program coverage, including positive aleniglipron results, was published earlier and does not directly explain today’s decline.